Vaccine demand slowdown and portfolio realignment reshape Singapore’s biomedical landscape
Singapore’s biomedical sector is facing a fresh adjustment as German biotech firm BioNTech moves to shut its Tuas site by February 2027. The decision reflects a wider shift in the global pharmaceutical industry as firms rethink manufacturing capacity after the pandemic boom.
BioNTech Pulls Back From Singapore Manufacturing
BioNTech said it will close its planned Singapore site by the end of February 2027 after what it described as a comprehensive review, adding that the move is part of efforts to align capacity with its clinical portfolio and long-term strategy. The company currently has 85 employees at the Singapore site and said it will support affected staff through the transition. BioNTech had acquired the former Novartis facility in Tuas in 2022 as part of its regional expansion strategy, with plans for it to serve as its regional headquarters and first mRNA manufacturing facility in Singapore.
Falling Vaccine Demand Drives Strategic Reset
The decision reflects a steep decline in Covid-19 vaccine demand after the pandemic, alongside slower progress in bringing new therapies, including cancer vaccines, to market. BioNTech has projected a 25 percent revenue drop in 2026 despite modest growth in 2025, highlighting how pandemic-era expansion is giving way to a more cautious and targeted business approach.
MSD Closure Signals Broader Industry Trend
BioNTech’s move follows US pharmaceutical firm MSD’s decision to shut one of its Tuas manufacturing sites, part of wider cost-cutting efforts aimed at saving US$3 billion, or approx. S$240,000. While MSD continues to operate other facilities in Singapore, both cases point to a broader industry shift as companies reassess global manufacturing footprints and pivot toward new growth areas.
Singapore’s Biomedical Sector Remains Resilient
Despite these closures, Singapore’s biomedical sciences sector continues to be a key economic pillar, contributing 1.9 percent of GDP in 2024 with an output exceeding S$32 billion and employing over 26,000 people. Authorities including the Economic Development Board are working with companies, Workforce Singapore, and NTUC to support affected workers and facilitate job transitions.
Long Term Outlook Still Positive
Singapore remains home to eight of the world’s top 10 biopharma firms, including Pfizer, AstraZeneca, and Johnson & Johnson, reinforcing its position as a regional life sciences hub. While individual companies adjust strategies, the broader ecosystem continues to attract investment, supported by strong infrastructure, talent, and policy stability.
BioNTech’s exit from Singapore manufacturing highlights how quickly global biotech strategies can change once emergency pandemic demand fades. For Singaporeans, the immediate issue is the impact on jobs and confidence, but the broader picture still points to a resilient biomedical sector with deep capabilities and long-term relevance. For Indonesians and Singaporeans, the development also shows how life sciences investment across the region is becoming more selective, with firms focusing less on rapid expansion and more on portfolio fit, efficiency, and sustainable returns.
Sources: Straits Times (2026) , ASEAN Briefing (2026)
Keywords: BioNTech Singapore Closure, MSD Singapore Site, Biomedical Industry Singapore, Pharma Manufacturing Shift, Tuas Biotech Plant, Singapore Life Sciences
